First National Bank of Omaha cut its holdings in shares of AbbVie Inc (NYSE:ABBV) by 8.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,715 shares of the company’s stock after selling 1,400 shares during the quarter. First National Bank of Omaha’s holdings in AbbVie were worth $1,190,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. Keeler Thomas Management LLC grew its position in shares of AbbVie by 19.2% in the 3rd quarter. Keeler Thomas Management LLC now owns 29,142 shares of the company’s stock worth $2,206,000 after acquiring an additional 4,704 shares in the last quarter. Bartlett & Co. LLC grew its position in shares of AbbVie by 17.0% in the 3rd quarter. Bartlett & Co. LLC now owns 128,900 shares of the company’s stock worth $9,760,000 after acquiring an additional 18,767 shares in the last quarter. NTV Asset Management LLC grew its position in shares of AbbVie by 0.4% in the 3rd quarter. NTV Asset Management LLC now owns 36,966 shares of the company’s stock worth $2,799,000 after acquiring an additional 154 shares in the last quarter. M Holdings Securities Inc. grew its position in shares of AbbVie by 8.7% in the 3rd quarter. M Holdings Securities Inc. now owns 17,005 shares of the company’s stock worth $1,288,000 after acquiring an additional 1,358 shares in the last quarter. Finally, D Orazio & Associates Inc. grew its position in shares of AbbVie by 24.8% in the 3rd quarter. D Orazio & Associates Inc. now owns 1,872 shares of the company’s stock worth $142,000 after acquiring an additional 372 shares in the last quarter. Institutional investors own 68.38% of the company’s stock.
NYSE:ABBV opened at $85.21 on Friday. AbbVie Inc has a 12-month low of $62.66 and a 12-month high of $94.98. The firm has a market capitalization of $121.00 billion, a P/E ratio of 10.77, a P/E/G ratio of 2.04 and a beta of 0.98. The business has a 50 day simple moving average of $76.28 and a 200 day simple moving average of $73.49.
AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, November 1st. The company reported $2.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.29 by $0.04. AbbVie had a negative return on equity of 155.71% and a net margin of 9.90%. The business had revenue of $8.48 billion during the quarter, compared to analyst estimates of $8.37 billion. During the same quarter in the previous year, the firm posted $2.14 EPS. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. As a group, sell-side analysts forecast that AbbVie Inc will post 8.93 EPS for the current fiscal year.
The business also recently disclosed a — dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be given a dividend of $1.07 per share. The ex-dividend date of this dividend is Friday, October 11th. This represents a yield of 6.4%. AbbVie’s dividend payout ratio is currently 54.11%.
Several brokerages have recently commented on ABBV. Cowen set a $90.00 target price on AbbVie and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Citigroup upgraded AbbVie from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $87.00 to $90.00 in a research report on Thursday, September 26th. UBS Group upgraded AbbVie from a “neutral” rating to a “buy” rating and decreased their target price for the stock from $85.00 to $79.00 in a research report on Thursday, September 12th. Piper Jaffray Companies lifted their target price on AbbVie from $81.00 to $90.00 in a research report on Friday, November 1st. Finally, ValuEngine upgraded AbbVie from a “strong sell” rating to a “sell” rating in a research report on Monday, September 30th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and seven have issued a buy rating to the company. AbbVie presently has a consensus rating of “Hold” and an average price target of $84.88.
In other AbbVie news, EVP Timothy J. Richmond sold 15,515 shares of AbbVie stock in a transaction on Friday, September 27th. The stock was sold at an average price of $75.02, for a total transaction of $1,163,935.30. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Vice Chairman Laura J. Schumacher bought 25,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were acquired at an average cost of $70.42 per share, for a total transaction of $1,760,500.00. Following the purchase, the insider now directly owns 164,838 shares in the company, valued at $11,607,891.96. The disclosure for this purchase can be found here. Insiders have purchased a total of 88,077 shares of company stock valued at $4,401,551 in the last 90 days. Insiders own 0.08% of the company’s stock.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Recommended Story: What Does a Sell-Side Analyst Rating Mean?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.